Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

Introduction Treatment resistant depression (TRD) is estimated to affect 10–30% of patients with major depressive disorder (Al‑Harbi et al. Patient Prefer Adherence 2012; 6 369–88). Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin norepin...

Full description

Bibliographic Details
Main Authors: A. Reif, A. E. Anıl Yağcıoğlu, A. Luts, T. Messer, R. Nielsen, J. Buyze, T. Ito, Y. Kambarov, S. Mulhern Haughey, B. Rive, I. Usankova, C. von Holt, Y. Godinov
Format: Article
Language:English
Published: Cambridge University Press 2023-03-01
Series:European Psychiatry
Online Access:https://www.cambridge.org/core/product/identifier/S0924933823002729/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S0924933823002729/type/journal_article

Similar Items